Ignyta will work with Leiden University Medical Center on new biomarker research involving patients with early synovitis and rheumatoid arthritis. The goal of the work is to develop a diagnostic test for patients with early-stage rheumatoid arthritis, and so the joint effort will focus on assessing epigenetic biomarker signatures for both conditions. Such a diagnostic, ideally, will be designed with both high specificity and high sensitivity. Ignyta launched two years ago and is based in San Diego. Release